FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804051772> ?p ?o ?g. }

• W2804051772 endingPage "1038.e5" @default.
• W2804051772 startingPage "1034" @default.
• W2804051772 abstract "Background Dipeptidyl peptidase 4 inhibitors (DPP4is) used to treat diabetes have been reported to be associated with an increased risk of bullous pemphigoid (BP). There are no previous reports analyzing the risk of BP in patients who are using other diabetes medications. Objective To evaluate the association between diabetes medications other than DPP4i and development of BP. Methods We investigated the prevalence of diabetes among patients with BP and the association between the use of diabetes drugs (excluding DPP4i, metformin, and insulin) and BP by analyzing national Finnish registry data for 3397 patients with BP and 12,941 patients with basal cell carcinoma as controls. Results Our results show that 19.6% of patients with BP have type 2 diabetes. Use of none of the investigated medications was associated with an increased risk of BP. Limitations Because this was a registry-based study, it was not possible to verify the accuracy of the diagnoses. The risk of BP in users of glucagon-like peptide 1 receptor agonists could not be analyzed. Conclusion Our study shows that the investigated diabetes drugs are not associated with an increased risk of BP in a Finnish patient database, indicating they can be safely used in this population. Generalization of these results to other populations will require further study. Dipeptidyl peptidase 4 inhibitors (DPP4is) used to treat diabetes have been reported to be associated with an increased risk of bullous pemphigoid (BP). There are no previous reports analyzing the risk of BP in patients who are using other diabetes medications. To evaluate the association between diabetes medications other than DPP4i and development of BP. We investigated the prevalence of diabetes among patients with BP and the association between the use of diabetes drugs (excluding DPP4i, metformin, and insulin) and BP by analyzing national Finnish registry data for 3397 patients with BP and 12,941 patients with basal cell carcinoma as controls. Our results show that 19.6% of patients with BP have type 2 diabetes. Use of none of the investigated medications was associated with an increased risk of BP. Because this was a registry-based study, it was not possible to verify the accuracy of the diagnoses. The risk of BP in users of glucagon-like peptide 1 receptor agonists could not be analyzed. Our study shows that the investigated diabetes drugs are not associated with an increased risk of BP in a Finnish patient database, indicating they can be safely used in this population. Generalization of these results to other populations will require further study." @default.
• W2804051772 created "2018-06-01" @default.
• W2804051772 creator A5024812595 @default.
• W2804051772 creator A5028661203 @default.
• W2804051772 creator A5041094138 @default.
• W2804051772 creator A5043677342 @default.
• W2804051772 creator A5044013990 @default.
• W2804051772 creator A5052001648 @default.
• W2804051772 creator A5058173261 @default.
• W2804051772 date "2018-12-01" @default.
• W2804051772 modified "2023-10-07" @default.
• W2804051772 title "Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study" @default.
• W2804051772 cites W1525088973 @default.
• W2804051772 cites W1836292197 @default.
• W2804051772 cites W1893849455 @default.
• W2804051772 cites W1969145745 @default.
• W2804051772 cites W1976227150 @default.
• W2804051772 cites W2011242327 @default.
• W2804051772 cites W2052165797 @default.
• W2804051772 cites W2054438253 @default.
• W2804051772 cites W2076982024 @default.
• W2804051772 cites W2085109894 @default.
• W2804051772 cites W2086492784 @default.
• W2804051772 cites W2333003991 @default.
• W2804051772 cites W2460486510 @default.
• W2804051772 cites W2555727277 @default.
• W2804051772 cites W2556552479 @default.
• W2804051772 cites W2591088772 @default.
• W2804051772 cites W2613446307 @default.
• W2804051772 cites W2724143375 @default.
• W2804051772 cites W2778763028 @default.
• W2804051772 cites W2785773046 @default.
• W2804051772 cites W4210970777 @default.
• W2804051772 cites W4214911496 @default.
• W2804051772 doi "https://doi.org/10.1016/j.jaad.2018.05.030" @default.
• W2804051772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29803903" @default.
• W2804051772 hasPublicationYear "2018" @default.
• W2804051772 type Work @default.
• W2804051772 sameAs 2804051772 @default.
• W2804051772 citedByCount "38" @default.
• W2804051772 countsByYear W28040517722018 @default.
• W2804051772 countsByYear W28040517722019 @default.
• W2804051772 countsByYear W28040517722020 @default.
• W2804051772 countsByYear W28040517722021 @default.
• W2804051772 countsByYear W28040517722022 @default.
• W2804051772 countsByYear W28040517722023 @default.
• W2804051772 crossrefType "journal-article" @default.
• W2804051772 hasAuthorship W2804051772A5024812595 @default.
• W2804051772 hasAuthorship W2804051772A5028661203 @default.
• W2804051772 hasAuthorship W2804051772A5041094138 @default.
• W2804051772 hasAuthorship W2804051772A5043677342 @default.
• W2804051772 hasAuthorship W2804051772A5044013990 @default.
• W2804051772 hasAuthorship W2804051772A5052001648 @default.
• W2804051772 hasAuthorship W2804051772A5058173261 @default.
• W2804051772 hasBestOaLocation W28040517722 @default.
• W2804051772 hasConcept C126322002 @default.
• W2804051772 hasConcept C134018914 @default.
• W2804051772 hasConcept C156490143 @default.
• W2804051772 hasConcept C159654299 @default.
• W2804051772 hasConcept C203014093 @default.
• W2804051772 hasConcept C2777180221 @default.
• W2804051772 hasConcept C2778075117 @default.
• W2804051772 hasConcept C2778763485 @default.
• W2804051772 hasConcept C2779252107 @default.
• W2804051772 hasConcept C2780323712 @default.
• W2804051772 hasConcept C2908647359 @default.
• W2804051772 hasConcept C555293320 @default.
• W2804051772 hasConcept C71924100 @default.
• W2804051772 hasConcept C99454951 @default.
• W2804051772 hasConceptScore W2804051772C126322002 @default.
• W2804051772 hasConceptScore W2804051772C134018914 @default.
• W2804051772 hasConceptScore W2804051772C156490143 @default.
• W2804051772 hasConceptScore W2804051772C159654299 @default.
• W2804051772 hasConceptScore W2804051772C203014093 @default.
• W2804051772 hasConceptScore W2804051772C2777180221 @default.
• W2804051772 hasConceptScore W2804051772C2778075117 @default.
• W2804051772 hasConceptScore W2804051772C2778763485 @default.
• W2804051772 hasConceptScore W2804051772C2779252107 @default.
• W2804051772 hasConceptScore W2804051772C2780323712 @default.
• W2804051772 hasConceptScore W2804051772C2908647359 @default.
• W2804051772 hasConceptScore W2804051772C555293320 @default.
• W2804051772 hasConceptScore W2804051772C71924100 @default.
• W2804051772 hasConceptScore W2804051772C99454951 @default.
• W2804051772 hasIssue "6" @default.
• W2804051772 hasLocation W28040517721 @default.
• W2804051772 hasLocation W28040517722 @default.
• W2804051772 hasLocation W28040517723 @default.
• W2804051772 hasOpenAccess W2804051772 @default.
• W2804051772 hasPrimaryLocation W28040517721 @default.
• W2804051772 hasRelatedWork W1512997554 @default.
• W2804051772 hasRelatedWork W2301714968 @default.
• W2804051772 hasRelatedWork W2793480170 @default.
• W2804051772 hasRelatedWork W2809613659 @default.
• W2804051772 hasRelatedWork W2883824169 @default.
• W2804051772 hasRelatedWork W2948314571 @default.
• W2804051772 hasRelatedWork W3195815739 @default.
• W2804051772 hasRelatedWork W4232552335 @default.
• W2804051772 hasRelatedWork W2496840989 @default.

• next